| Primary |
| Toxoplasmosis |
26.9% |
| Cerebral Toxoplasmosis |
17.2% |
| Drug Use For Unknown Indication |
10.8% |
| Gastrointestinal Disorder |
8.6% |
| Congenital Toxoplasmosis |
6.5% |
| Hiv Infection |
6.5% |
| Prophylaxis |
4.3% |
| Eye Infection Toxoplasmal |
3.2% |
| Cytogenetic Abnormality |
2.2% |
| Epilepsy |
2.2% |
| Lung Infection |
2.2% |
| Toxoplasmosis |
1.1% |
| Affective Disorder |
1.1% |
| Antifungal Prophylaxis |
1.1% |
| Brain Oedema |
1.1% |
| Convulsion Prophylaxis |
1.1% |
| Electrolyte Substitution Therapy |
1.1% |
| Encephalitis |
1.1% |
| Intertrigo |
1.1% |
| Malaria Prophylaxis |
1.1% |
|
| Neutropenia |
13.5% |
| Vomiting |
10.8% |
| Nephrolithiasis |
8.1% |
| Thrombocytopenia |
8.1% |
| Drug Ineffective |
5.4% |
| Pyrexia |
5.4% |
| Supraventricular Tachycardia |
5.4% |
| Tongue Ulceration |
5.4% |
| Toxoplasmosis |
5.4% |
| Tremor |
5.4% |
| Agranulocytosis |
2.7% |
| Blindness |
2.7% |
| Bone Marrow Failure |
2.7% |
| Cardiac Murmur |
2.7% |
| Hepatic Enzyme Increased |
2.7% |
| Hypophagia |
2.7% |
| Off Label Use |
2.7% |
| Oral Pain |
2.7% |
| Pancytopenia |
2.7% |
| Papilloedema |
2.7% |
|
| Secondary |
| Hiv Infection |
15.6% |
| Cerebral Toxoplasmosis |
12.1% |
| Sepsis |
7.9% |
| Product Used For Unknown Indication |
6.7% |
| Toxoplasmosis |
6.7% |
| Ear Infection |
6.0% |
| Brain Oedema |
5.7% |
| Hallucination |
5.4% |
| Supplementation Therapy |
5.1% |
| Acne |
4.8% |
| Mycobacterium Avium Complex Infection |
4.4% |
| Thrombosis Prophylaxis |
4.4% |
| Drug Use For Unknown Indication |
3.2% |
| Pyrexia |
2.5% |
| Encephalitis Herpes |
2.2% |
| Hyperglycaemia |
2.2% |
| Brain Abscess |
1.3% |
| Cytomegalovirus Enterocolitis |
1.3% |
| Delirium |
1.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.3% |
|
| Renal Failure Acute |
15.4% |
| Pancytopenia |
12.8% |
| Toxic Epidermal Necrolysis |
12.8% |
| Platelet Count Decreased |
10.3% |
| Stevens-johnson Syndrome |
10.3% |
| Thrombocytopenia |
10.3% |
| Agranulocytosis |
5.1% |
| Tubulointerstitial Nephritis |
5.1% |
| Blindness Unilateral |
2.6% |
| Delirium |
2.6% |
| Hepatotoxicity |
2.6% |
| Optic Ischaemic Neuropathy |
2.6% |
| Pyrexia |
2.6% |
| Urinary Tract Infection |
2.6% |
| White Blood Cell Count Decreased |
2.6% |
|
| Concomitant |
| Hiv Infection |
30.1% |
| Product Used For Unknown Indication |
23.8% |
| Prophylaxis |
6.6% |
| Acquired Immunodeficiency Syndrome |
5.3% |
| Antiretroviral Therapy |
3.8% |
| Graft Versus Host Disease |
3.8% |
| Multiple Myeloma |
3.1% |
| Infection Prophylaxis |
2.5% |
| Toxoplasmosis |
2.5% |
| Uveitis |
2.5% |
| Antibiotic Prophylaxis |
2.2% |
| Cerebral Toxoplasmosis |
2.2% |
| Anaemia |
1.9% |
| Hiv Infection Cdc Category C3 |
1.9% |
| Diarrhoea |
1.6% |
| Drug Use For Unknown Indication |
1.6% |
| Cryptococcosis |
1.3% |
| Haematopoietic Stem Cell Mobilisation |
1.3% |
| Pyrexia |
1.3% |
| Central Nervous System Infection |
0.9% |
|
| Uveitis |
10.6% |
| Aphasia |
8.5% |
| Renal Failure |
8.5% |
| Death |
6.4% |
| Toxoplasmosis |
6.4% |
| Vomiting |
6.4% |
| Weight Decreased |
6.4% |
| Graft Versus Host Disease |
4.3% |
| Hyperthyroidism |
4.3% |
| Multi-organ Failure |
4.3% |
| Progressive Multifocal Leukoencephalopathy |
4.3% |
| Pyrexia |
4.3% |
| Respiratory Tract Infection |
4.3% |
| Septic Shock |
4.3% |
| Stevens-johnson Syndrome |
4.3% |
| White Blood Cell Count Decreased |
4.3% |
| Alanine Aminotransferase Increased |
2.1% |
| Anaemia |
2.1% |
| Aspartate Aminotransferase Increased |
2.1% |
| Blindness |
2.1% |
|
